Amneal Pharmaceuticals, Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Amneal Pharmaceuticals, Llc Pharmaceutical Import Records from India — 9 Products, $16.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amneal Pharmaceuticals, Llc — Pharmaceutical Importer Profile (2026) | 9 Products, $16.7M Trade | TransData Nexus

Amneal Pharmaceuticals, Llc

Pharmaceutical Importer · United States · Vitamins & Supplements Focus · $16.7M Total Trade · DGFT Verified

Amneal Pharmaceuticals, Llc is a pharmaceutical importer based in United States with a total trade value of $16.7M across 9 products in 6 therapeutic categories. Based on 352 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Amneal Pharmaceuticals, Llc sources from 5 verified Indian suppliers, with Amneal Pharmaceuticals Private Limited accounting for 99.7% of imports.

Amneal Pharmaceuticals, Llc — Import Portfolio & Supplier Network

Amneal Pharmaceuticals, Llc import network — 9 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Amneal Pharmaceuticals, Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Amneal Pharmaceuticals Private Limited	$83.0M	2,337	99.7%
Amneal Injectables Private Limited	$178.8K	5	0.2%
Strides Pharma Science Limited	$100.0K

What Formulations Does Amneal Pharmaceuticals, Llc Import?

Formulation	Value	Ships
Gabapentin capsules, USP 300MG ndc	$2.7M	54
Colestipol hydrochloride tablets, USP	$2.6M	52
Potassium chloride extended-release	$2.2M	60
Oseltamivir phosphate capsules, 75 MG	$1.6M	33
Spironolactone tablets,usp25mg ndc	$1.5M	31
Divalproex sodium er TAB 500MG ndc	$1.4M	34
Spironolactone tablets,usp50mg ndc	$1.3M	27
Naproxen tablets, USP 500 MG ndc	$1.3M	25
Colestipol hydrochloride tablets, USP 1gram ndc 0115-5211-16 fda product code 62 b d e 03 anda # 077510 unit Pack	$1.2M	24
Spironolactonetablets,usp100mg ndc	$1.2M	24
Sucralfate tablets, USP 1 g ndc 60219-1656-01 fda product code 60 s c a 26 anda# 215576 unit Pack	$1.1M	29
Hydroxyzine pamoate capsules,USP 50 MG	$994.8K	21
Sevelamer carbonate tablets800mg ndc 65162-058-27 fda product code 63 l c a 03 anda # 207288 unit Pack	$900.0K	18
Pyridostigmine bromide tabletsusp 60 mgndc 0115-3511-01 fda product code 63 n ca 09 anda # a040502 unit Pack	$853.3K	19
Gabapentin capsules, USP 300MG ndc 65162-0102-50 fda product code 61 n c e 69 anda # 78428 unit Pack	$817.4K	17

Amneal Pharmaceuticals, Llc imports 511 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 9 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Magnesium	Vitamins & Supplements	$5.4M	108	1.5%	10
2	Tramadol	Analgesics & Antipyretics	$3.5M	69	0.6%	7
3	Calcium	Vitamins & Supplements	$3.1M	62	0.3%	16
4	Iron	Vitamins & Supplements	$1.3M	26	0.3%	15
5	Spironolactone	Diuretics	$1.3M	26	0.7%	7
6	Phenylephrine	Respiratory & OTC	$1.2M	32	1.4%	16
7	Naproxen	Analgesics & Antipyretics	$550.0K	11	0.4%	18
8	Warfarin	Cardiovascular	$343.1K	16	4.6%	6
9	Azathioprine	Immunosuppressants	$100.0K	2	0.3%	17

Amneal Pharmaceuticals, Llc imports 9 pharmaceutical products across 6 categories into United States totaling $16.7M.

Amneal Pharmaceuticals, Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Amneal Pharmaceuticals LLC is a U.S.-based pharmaceutical company specializing in the development, manufacturing, and distribution of generic and specialty drug products. Founded in 2002 by brothers Chirag and Chintu Patel, the company is headquartered in Bridgewater, New Jersey. Amneal has grown to become one of the largest manufacturers of generic drugs in the United States, offering a diverse portfolio that includes over 290 products across various therapeutic areas.

In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc., forming Amneal Pharmaceuticals, Inc. This strategic move expanded the company's capabilities and market presence. The merger was valued at $1.45 billion and required the divestiture of several marketed products and development projects as a condition of approval.

Amneal's product offerings span complex generics, injectables, biosimilars, and specialty medicines, with a focus on central nervous system and endocrine disorders. The company operates manufacturing facilities in New Jersey, New York, India, and Ireland, and has distribution and commercial operations in Glasgow, Kentucky.

2Distribution Network

Amneal Pharmaceuticals LLC has established a robust distribution network to ensure the efficient delivery of its products across the United States and internationally. The company operates manufacturing plants in Branchburg and Piscataway, New Jersey; Brookhaven and Hauppauge, New York; India; and Ireland. Additionally, Amneal has distribution and commercial operations in Glasgow, Kentucky, facilitating nationwide coverage.

The company's logistics capabilities are designed to support a diverse product portfolio, including complex generics, injectables, biosimilars, and specialty medicines. By leveraging its manufacturing and distribution facilities, Amneal ensures timely and efficient delivery of its products to meet the needs of healthcare providers and patients across various regions.

3Industry Role

Amneal Pharmaceuticals LLC plays a significant role in the United States pharmaceutical supply chain as a developer, manufacturer, and distributor of generic and specialty drug products. The company's extensive portfolio and manufacturing capabilities position it as a key player in providing affordable and accessible medications to the U.S. market.

Through its Specialty segment, Amneal also markets a portfolio of branded pharmaceutical products focused on central nervous system and endocrine disorders. This diversification allows the company to address a broader range of medical needs and contribute to the overall healthcare landscape in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Amneal Pharmaceuticals, Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Amneal Pharmaceuticals LLC's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imported pharmaceutical formulations originating from a single supplier, Amneal Pharmaceuticals Private Limited. This supplier accounted for $83.0 million in imports, representing 99.7% of the total value. The remaining imports were sourced from Amneal Injectables Private Limited ($179K, 0.2%), Strides Pharma Science Limited ($100K, 0.1%), Puniska Healthcare Private Limited ($805, 0.0%), and Steriscience Specialties Private Limited ($419, 0.0%).

This sourcing pattern indicates a strategic choice to maintain a streamlined supply chain, potentially benefiting from economies of scale and simplified logistics. However, such concentration also introduces risks related to supplier dependency, including potential disruptions due to regulatory changes, supply chain interruptions, or quality control issues.

The stability of the relationship with Amneal Pharmaceuticals Private Limited is crucial for Amneal Pharmaceuticals LLC's operations. The high volume of imports from this supplier suggests a long-standing and reliable partnership. Nonetheless, the company should continuously assess and manage risks associated with this concentration to ensure a resilient and adaptable supply chain.

2Supply Chain Resilience

Amneal Pharmaceuticals LLC's supply chain resilience is closely tied to its sourcing strategy, which is heavily concentrated on a single supplier, Amneal Pharmaceuticals Private Limited. This concentration can lead to vulnerabilities, particularly if the supplier faces operational challenges, regulatory issues, or geopolitical disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all drugs entering the U.S. market meet standards for quality, safety, and effectiveness.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which outlines requirements for drug approval, labeling, and manufacturing practices. The Drug Enforcement Administration (DEA) also regulates controlled substances, imposing additional requirements for their importation.

For Indian pharmaceutical companies exporting to the U.S., obtaining FDA approval for each drug product is mandatory. This process involves submitting an Abbreviated New Drug Application (ANDA) for generics or a New Drug Application (NDA) for new drugs, demonstrating that the product is bioequivalent to its brand-name counterpart and meets all FDA standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All foreign drug establishments whose products are imported must register with the FDA and list all their drug products in commercial distribution in the U.S.

Good Manufacturing Practice (GMP) certification is essential for ensuring product quality and safety. The FDA recognizes GMP certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Amneal Pharmaceuticals LLC must ensure their manufacturing facilities comply with these recognized GMP standards.

Amneal Pharmaceuticals, Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Amneal Pharmaceuticals LLC's product strategy focuses on providing a diverse range of pharmaceutical products across various therapeutic areas. The company's portfolio includes complex generics, injectables, biosimilars, and specialty medicines, addressing conditions such as central nervous system and endocrine disorders.

The market demand for affordable and accessible medications drives these imports. By sourcing products from India, Amneal leverages cost-effective manufacturing capabilities while ensuring compliance

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Amneal Pharmaceuticals, Llc

What products does Amneal Pharmaceuticals, Llc import from India?

Amneal Pharmaceuticals, Llc imports 9 pharmaceutical products across 6 categories. Top imports: Magnesium ($5.4M), Tramadol ($3.5M), Calcium ($3.1M), Iron ($1.3M), Spironolactone ($1.3M).

Who supplies pharmaceuticals to Amneal Pharmaceuticals, Llc from India?

Amneal Pharmaceuticals, Llc sources from 5 verified Indian suppliers. The primary supplier is Amneal Pharmaceuticals Private Limited (99.7% of imports, $83.0M).

What is Amneal Pharmaceuticals, Llc's total pharmaceutical import value?

Amneal Pharmaceuticals, Llc's total pharmaceutical import value from India is $16.7M, based on 352 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Amneal Pharmaceuticals, Llc focus on?

Amneal Pharmaceuticals, Llc imports across 6 categories. The largest: Vitamins & Supplements (58.7%), Analgesics & Antipyretics (23.9%), Diuretics (7.8%).

Get Full Amneal Pharmaceuticals, Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.